Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single centre, prospective one-year observational cohort study of the first 100 patients treated.

In Dermatology
by ClinOwl

Dupilumab (Dupixent®) is the first biologic drug licensed for treatment of adults with atopic dermatitis (AD). Data regarding its long-term real-world effectiveness and tolerability are limited. We report comprehensive outcome […]